[1] Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev, 2005; 18, 326−82. doi:  10.1128/CMR.18.2.326-382.2005
[2] Hewlett EL, Edwards KM. Pertussis — not just for kids. N Engl J Med, 2005; 352, 1215−22. doi:  10.1056/NEJMcp041025
[3] Bento AI, Riolo MA, Choi YH, et al. Core pertussis transmission groups in England and Wales: a tale of two eras. Vaccine, 2018; 36, 1160−6. doi:  10.1016/j.vaccine.2018.01.046
[4] Decker MD, Edwards KM, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics, 1995; 96, 557−66.
[5] Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med, 1996; 334, 341−8.
[6] Centers for Disease Control and Prevention (CDC). Notice to readers: final 2012 reports of nationally notifiable infectious diseases. MMWR Morb Mortal Wkly Rep, 2013; 62, 669−82.
[7] Dey A, Knox S, Wang H, et al. Summary of national surveillance data on vaccine preventable diseases in Australia, 2008-2011. Commun Dis Intell Q Rep, 2016; 40 Suppl, S1-70.
[8] Miyaji Y, Otsuka N, Toyoizumi-Ajisaka H, et al. Genetic analysis of Bordetella pertussis isolates from the 2008-2010 pertussis epidemic in Japan. PLoS One, 2013; 8, e77165. doi:  10.1371/journal.pone.0077165
[9] Sheridan SL, Frith K, Snelling TL, et al. Waning vaccine immunity in teenagers primed with whole cell and acellular pertussis vaccine: recent epidemiology. Expert Rev Vaccines, 2014; 13, 1081−106. doi:  10.1586/14760584.2014.944167
[10] Tartof SY, Lewis M, Kenyon C, et al. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics, 2013; 131, e1047−52. doi:  10.1542/peds.2012-1928
[11] Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci USA, 2014; 111, 787−92. doi:  10.1073/pnas.1314688110
[12] WHO. Pertussis.https://www.who.int/health-topics/pertussis. [2022-08-12].
[13] Zhang YX, Chen ZY, Zhao JH, et al. Increased susceptibility to pertussis in adults at childbearing age as determined by comparative seroprevalence study, China 2010-2016. J Infect, 2019; 79, 1−6. doi:  10.1016/j.jinf.2019.04.011
[14] Wang HB, Luo HM, Wen N, et al. Epidemiological analysis on pertussis in China during 2006-2010. Chin J Vaccines Immun, 2012; 18, 207−10. (In Chinese
[15] Lu HZ. Joinpoint regression analysis for the trends of pertussis incidence in China from 2005 to 2019. Chin J Public Health Manage, 2022; 38, 229−31. (In Chinese
[16] Centers for Disease Control and Prevention. Diseases and conditions. Pertussis (whooping cough). Surveillance and reporting.https://www.health.state.mn.us/diseases/pertussis/stats/index.html. [2022-08-12].
[17] European Centre for Disease Prevention and Control. Publications and data. Pertussis-annual epidemiological report.https://www.ecdc.europa.eu/en/publications-data/pertussis-annual-epidemiological-report-2017. [2022-08-12].
[18] Zepp F, Heininger U, Mertsola J, et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis, 2011; 11, 557−70. doi:  10.1016/S1473-3099(11)70007-X
[19] Yaari E, Yafe-Zimerman Y, Schwartz SB, et al. Clinical manifestations of Bordetella pertussis infection in immunized children and young adults. Chest, 1999; 115, 1254−8. doi:  10.1378/chest.115.5.1254
[20] Moriuchi T, Otsuka N, Hiramatsu Y, et al. A high seroprevalence of antibodies to pertussis toxin among Japanese adults: qualitative and quantitative analyses. PLoS One, 2017; 12, e0181181. doi:  10.1371/journal.pone.0181181
[21] Wiley KE, Zuo Y, Macartney KK, et al. Sources of pertussis infection in young infants: a review of key evidence informing targeting of the cocoon strategy. Vaccine, 2013; 31, 618−25. doi:  10.1016/j.vaccine.2012.11.052
[22] de Melker HE, Versteegh FGA, Conyn-Van Spaendonck MAE, et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J Clin Microbiol, 2000; 38, 800−6. doi:  10.1128/JCM.38.2.800-806.2000
[23] Qian XH, Tang SW, Li SH, et al. Monitoring on antibodies against whole cell Bordetella pertussis in healthy adolescents in Hongkou District, Shanghai City, China. Chin J Biol, 2015; 28, 1289−93. (In Chinese
[24] Shen WH, Lv YL, Liao MT, et al. Survey on antibody levels of rubella and pertussis in whole population of Zhaoqing City in 2020. Chin Commun Doct, 2022; 38, 151−3. (In Chinese
[25] Zhang DZ, Liu CT, Wan YH, et al. Pertussis antibody level in serum among the 605 healthy population from high-prevalence area, Guizhou. Mod Prev Med, 2018; 45, 164−8. (In Chinese
[26] Zhang Y, Huang HT, Gao ZG, et al. A sera-epidemiological study on pertussis immunity levels among community populations and an analysis of the underlying factors in Tianjin China. Vaccine, 2015; 33, 7183−7. doi:  10.1016/j.vaccine.2015.10.133
[27] Xu YY, Xu EP, Liu SJ, et al. Seroepidemiology of pertussis in Hangzhou, China, during 2009-2017. Hum Vaccin Immunother, 2019; 15, 2564−70. doi:  10.1080/21645515.2019.1608130
[28] WHO. Pertussis vaccines: WHO position paper, August 2015—recommendations. Vaccine, 2016; 34, 1423-5.
[29] Campbell P, McIntyre P, Quinn H, et al. Increased population prevalence of low pertussis toxin antibody levels in young children preceding a record pertussis epidemic in Australia. PLoS One, 2012; 7, e35874. doi:  10.1371/journal.pone.0035874
[30] Guiso N, Berbers G, Fry NK, et al. What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. Eur J Clin Microbiol Infect Dis, 2011; 30, 307−12. doi:  10.1007/s10096-010-1104-y
[31] Markey K, Douglas-Bardsley A, Asokanathan C, et al. Improvement in serological diagnosis of pertussis by external quality assessment. J Med Microbiol, 2019; 68, 741−7. doi:  10.1099/jmm.0.000926
[32] European Centre for Disease Prevention and Control (ECDC). Laboratory diagnosis and molecular surveillance of Bordetella pertussis.https://www.ecdc.europa.eu/en/publications-data/bordetella-pertussis-laboratory-diagnosis-and-molecular-surveillance. [2022-12-21].
[33] Li YT, Luo XQ, Zhong XB, et al. Seroprevalences of antibodies against pertussis, diphtheria, tetanus, measles, mumps and rubella: a cross-sectional study in children following vaccination procedure in Guangzhou, China. Vaccine, 2020; 38, 3960−7. doi:  10.1016/j.vaccine.2020.03.056
[34] Zhang ZJZ, Pan JB, Chen M, et al. Seroepidemiology of pertussis in China: a population-based, cross-sectional study. Vaccine, 2021; 39, 1687−92. doi:  10.1016/j.vaccine.2021.02.032
[35] Yao N, Zeng Q, Wang Q. Seroepidemiology of diphtheria and pertussis in Chongqing, China: serology-based evidence of Bordetella pertussis infection. Public Health, 2018; 156, 60−6. doi:  10.1016/j.puhe.2017.12.009
[36] Chen ZY, Pang J, Zhang N, et al. Seroprevalence study of pertussis in adults at childbearing age and young infants reveals the necessity of booster immunizations in adults in China. Vaccines (Basel), 2022; 10, 84. doi:  10.3390/vaccines10010084
[37] Chen Q, Wang W, Shi XY, et al. Seroepidemiology of pertussis in the east of China: estimates of incidence of infection in adolescents and adults pre- and post-COVID-19. Front Public Health, 2022; 10, 1054617. doi:  10.3389/fpubh.2022.1054617
[38] Wehlin L, Ljungman M, Kühlmann-Berenzon S, et al. Pertussis seroprevalence among adults of reproductive age (20-39 years) in fourteen European countries. APMIS, 2021; 129, 556−65. doi:  10.1111/apm.13165
[39] Wang CQ, Zhu QR. Seroprevalence of Bordetella pertussis antibody in children and adolescents in China. Pediatr Infect Dis J, 2011; 30, 593−6. doi:  10.1097/INF.0b013e31820eaf88
[40] Xu YH, Wang LC, Xu J, et al. Seroprevalence of pertussis in China: need to improve vaccination strategies. Hum Vaccin Immunother, 2014; 10, 192−8. doi:  10.4161/hv.26335
[41] Wendelboe AM, Van Rie A, Salmaso S, et al. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J, 2005; 24, S58−61. doi:  10.1097/01.inf.0000160914.59160.41
[42] Huang HT, Gao P, Gao ZG, et al. A big pertussis outbreak in a primary school with high vaccination coverage in northern China: an evidence of the emerging of the disease in China. Vaccine, 2018; 36, 7950−5. doi:  10.1016/j.vaccine.2018.11.009
[43] Liu XG, Wang ZG, Zhang JS, et al. Pertussis outbreak in a primary school in China: infection and transmission of the macrolide-resistant Bordetella pertussis. Pediatr Infect Dis J, 2018; 37, e145−8. doi:  10.1097/INF.0000000000001814
[44] Wang LC, Lei DL, Zhang SM. Acellular pertussis vaccines in China. Vaccine, 2012; 30, 7174−8. doi:  10.1016/j.vaccine.2012.10.009
[45] Stefanelli P, Fazio C, Fedele G, et al. A natural pertactin deficient strain of Bordetella pertussis shows improved entry in human monocyte-derived dendritic cells. New Microbiol, 2009; 32, 159−66.
[46] Pawloski LC, Queenan AM, Cassiday PK, et al. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States. Clin Vaccine Immunol, 2014; 21, 119−25. doi:  10.1128/CVI.00717-13
[47] Yin ZY, Zheng CJ, Fang QJ, et al. Comparing the pertussis antibody levels of healthy children immunized with four doses of DTap-IPV/Hib (Pentaxim) combination vaccine and DTaP vaccine in Quzhou, China. Front Immunol, 2023; 13, 1055677. doi:  10.3389/fimmu.2022.1055677